Design and Optimization of Self Nano-Emulsifying Drug Delivery System Containing a New Anti-inflammatory Agent Pentagamavunon-0

Ika Yuni Astuti; Marchaban Marchaban; Ronny Martien; Agung Endro Nugroho

doi:10.22146/ijc.22640

Design and Optimization of Self Nano-Emulsifying Drug Delivery System Containing a New Anti-inflammatory Agent Pentagamavunon-0

https://doi.org/10.22146/ijc.22640

Ika Yuni Astuti^(1*), Marchaban Marchaban⁽²⁾, Ronny Martien⁽³⁾, Agung Endro Nugroho⁽⁴⁾

(1) Faculty of Pharmacy, University of Muhammadiyah Purwokerto, Jl. Raya Dukuhwaluh, Dukuhwaluh, Kembaran, Purwokerto 53182, Indonesia
(2) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Jl. Sekip Utara, Yogyakarta 55281, Indonesia
(3) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Jl. Sekip Utara, Yogyakarta 55281, Indonesia
(4) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Jl. Sekip Utara, Yogyakarta 55281, Indonesia
(*) Corresponding Author

Abstract

Pentagamavunon-0 is a potent anti-inflammatory drug. The oral bioavailability of PGV-0 is very low due to its low solubility in water. The aim of this study is to design and optimize SNEDDS formulation to improve dissolution of PGV-0 by Simplex Lattice Design. The independent variables were the amounts of oleic acid (X₁), Tween 20 and labrasol (X₂), and PEG 400 (X₃). The dependent variables were droplet size (Y₁), the concentration of PGV-0 dissolved in the 45^th min (C₄₅) (Y₂) and solubility of PGV-0 (Y₃) fitted to a quadratic model. The equation, contour plots, and overlay plot were constructed to determine the optimum formulation and to understand the responses to various combinations of components. The optimum formulation of SNEDDS consists of 18.6% oleic acid, 51.4% Tween 20:labrasol 1:1 and 30% PEG 400. The C₄₅ of the optimum formulation is 82.20%, significantly higher than unmodified PGV-0. The droplet size is 75.45 nm and solubility of PGV-0 is 31.80 mg/mL. The predicted values are not significantly different with the experimental values. The amount of oleic acid is the most influential factor to increase droplet size and decrease the C₄₅. The mostinfluential factor to increased C₄₅ is the amount of PEG 400.

Keywords

pentagamavunon-0; SNEDDS; simplex lattice design

Full Text:

Full Text PDF

References

[1] Sardjiman, 2000, Synthesis of a New Series of Curcumin Analogues, Biological Activities and Qualitative Structure-Activity Relationships, Dissertation, Universitas Gadjah Mada, Yogyakarta.

[2] Nugroho, A.E., Ikawati, Z., Sardjiman, and Maeyama, K., 2009, Effects of benzylidenecyclopentanone analogues of curcumin on histamine release from mast cells, Biol. Pharm. Bull., 32 (5), 842–849.

[3] Nugroho, A.E., Sardjiman, and Maeyama, K., 2010, Inhibitory effect of 2,5-bis(4-hydroxy-3-methoxybenzylidene) cyclopentanone on mast cell histamine mediated-rat paw edema, Thai J. Pharm. Sci., 34, 107–116.

[4] Oetari, R.A., Sardjiman, Yuwono, T., and Fudholi, A., 2003, Formulasi senyawa baru antiinflamasi PGV-0 dalam bentuk sediaan tablet, Indonesian J. Pharm., 14 (3), 160–168.

[5] Istyastono, E.P., Siwi, S.U., Utama, A.A., and Supardjan, A.M, 2004, Synthesis new potential anti-inflammatory agent sodium salt of Pentagamavunon-0, Indones. J. Chem., 4 (3), 180–185.

[6] Hakim, R.A., Nugroho, A.E., and Hakim, L., 2006, Profil farmakokinetika Pentagamavunon-0 setelah pemberian kalium Pentagamavunonat-0 secara oral pada tikus, Indonesian J. Pharm., 17 (4), 204–211.

[7] Windriyati, N.Y., Fudholi, A., and Oetari, A.R., 2006, Dissolution properties of solid dispersions of Pentagamavunon-0 with polyvinylpyrrolidone, Symposium Curcumin, 27, 1–5.

[8] Serajuddin, A.T., 2007, Salt formation to improve drug solubility, Adv. Drug Delivery Rev., 59 (7), 603–616.

[9] Chauhan, B., Shimpi, S., and Paradkan, A., 2005, Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique, AAPS PharmSciTech., 6(3), E405–E409.

[10] Wang, X., Michael, A., and Van den Mooter, G., 2005, Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole, Int. J. Pharm., 303 (1-2), 54–61.

[11] Rao, S.V.R., Yajurvedi, K., and Shao, J., 2008, Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: III. In vivo oral absorption study, Int. J. Pharm., 362 (1-2), 16–19.

[12] Cui, J., Yu, B., Zhao, Y., Zhu, W., Li, H., Lou, H., and Zhai, G., 2009, Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems, Int. J. Pharm., 371 (1-2),148–155.

[13] Zhao, L., Zhang, L., Meng, L., Wang, J., and Zhai, G., 2013, Design and evaluation of a self-microemulsifying drug delivery system for apigenin, Drug Dev. Ind. Pharm., 39 (5), 662–669.

[14] Departemen Kesehatan Republik Indonesia, 1995, Farmakope Indonesia, 4^th ed., Depkes RI, Jakarta.

[15] Yamagami, C., Araki, K., Ohnishi, K., Hanasato, K., Inaba, H., Aono, M., and Ohta, A., 1999, Measurement and prediction of hydrophobicity parameters for highly lipophilic compounds: Application of the HPLC column-switching technique to measurement of log P of diarylpyrazines, J. Pharm. Sci., 88 (12), 1299–1304.

[16] Yuwono, T., and Oetari, R.A. 2008, Stabilitas PGV-0 (Pentagamavunon-0) sebagai obat antiinflamasi dalam bentuk sediaan larutan cair, Indonesian J. Pharm., 15, 20–25.

[17] Basalious, E.B., Shawsky, N., and Badr-Eldin, S.M., 2010, SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: Development and optimization, Int. J. Pharm., 391 (1-2), 203–211.

[18] Gupta S., Kesarla, R., and Omri, A., 2013, Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems, ISRN Pharm., 848043.

[19] Kohli, K., Chopra, S., Dhar, D., Arora, S., and Khar, R.K., 2010, Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability, Drug Discovery Today, 15 (21-22), 958–965.

[20] Prajapati, K., and Patel, S., 2012, Micellization of Surfactants in mixed solvent of different polarity, Arch. Appl. Sci. Res., 4 (1), 662–668.

[21] Bandivadekar, M.M., Pancholi, S.S., Kaul-Ghanekar, R., Choudhari, A., and Koppikar S., 2012, Self-microemulsifying smaller molecular volume oil (Capmul MCM) using non-ionic surfactants: a delivery system for poorly water-soluble drug, Drug. Dev. Ind. Pharm., 38 (7), 883–892.

[22] Marasini, N., Yan, Y.D., Poudel, B.K., Choi, H.G., Yong, C.S. and Kim J.O., 2012, Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function, J. Pharm. Sci., 101 (12), 4584–4596.

DOI: https://doi.org/10.22146/ijc.22640